atorvastatin has been researched along with sulindac in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Xiao, H; Yang, CS | 1 |
| Benya, R; Chiorean, M; Della'Zanna, G; Gostout, C; Heigh, R; Lawson, MJ; Levine, J; Limburg, PJ; Mahoney, MR; Mandrekar, SJ; Richmond, E; Rodriguez, L; Schoen, RE; Smyrk, TC; Sontag, SJ; Stoffel, E; Weinberg, DS; Ziegler, KL | 1 |
| DeCastro, A; Janakiram, NB; Lee, HJ; Paul, S; Rao, CV; Reddy, BS; Simi, B; Smolarek, AK; So, JY; Steele, V; Suh, N; Wang, CX | 1 |
| Chang, WL; Clapper, ML; Cooper, HS; Devarajan, K; Hensley, HH; Jackson, C; Nguyen, MT; Riel, S; Vanderveer, LA; Zhou, Y | 1 |
| Chong, S; Huang, F; Lin, H; Su, Y; Wang, X; Yan, Z; Zeng, Z; Zhang, X | 1 |
2 review(s) available for atorvastatin and sulindac
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
1 trial(s) available for atorvastatin and sulindac
| Article | Year |
|---|---|
Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.
Topics: Aberrant Crypt Foci; Aged; Antineoplastic Agents; Atorvastatin; Colorectal Neoplasms; Dietary Fiber; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Male; Middle Aged; Pyrroles; Sulindac; Survival Rate; Treatment Outcome | 2011 |
6 other study(ies) available for atorvastatin and sulindac
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Azoxymethane; beta Catenin; Carcinogens; Colonic Neoplasms; Cyclin D1; eIF-2 Kinase; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Immunoenzyme Techniques; Interleukin-4; Male; Naproxen; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Inbred F344; Signal Transduction; Sulindac; Tumor Necrosis Factor-alpha | 2011 |
Differential preventive activity of sulindac and atorvastatin in Apc
Topics: Adenoma; Animals; Antineoplastic Agents; Atorvastatin; Colorectal Neoplasms; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Sulindac | 2018 |
Discovery of atorvastatin as a tetramer stabilizer of nuclear receptor RXRα through structure-based virtual screening.
Topics: Antineoplastic Agents; Atorvastatin; Binding Sites; Drug Evaluation, Preclinical; Humans; Ligands; MCF-7 Cells; Protein Binding; Protein Domains; Protein Multimerization; Protein Stability; Retinoid X Receptor alpha; Sulindac | 2019 |